Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
FOSTER CITY, Calif. & MUNICH–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) right this moment introduced it has entered right into a definitive settlement to purchase Tubulis GmbH, a non-public Germany-based, clinical-stage biotechnology firm creating next-generation antibody-drug conjugates (ADCs), constructing on Gilead’s oncology pipeline, targeted on addressing areas of excessive unmet want. The acquisition considerably expands Gilead’s…
